ClinicalTrials.gg
CompletedNCT03713619SUNSHINEUpdated Oct 9, 2024Results posted

This Was a Study of Efficacy and Safety of Two Secukinumab Dose Regimens in Subjects With Moderate to Severe Hidradenitis Suppurativa (HS).

A Phase 3 interventional study of secukinumab and Placebo in Hidradenitis Suppurativa, sponsored by Novartis Pharmaceuticals. Completed at 111 sites in 29 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-10-09.

Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
544
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 21 studies in Hidradenitis Suppurativa by Novartis — 9 open to participants now, 14 under way, 3 of them phase 3. Hidradenitis Suppurativa · Novartis.

Enrollment
6th of 10
544 · median 545
Started
2019
with 2 others
Phase 3
6 of 21
1 open now
Registered
2nd of 21
by date

Among the 21 studies in Hidradenitis Suppurativa by Novartis, this one is the 6th largest by enrollment of the 10 interventional ones that give a count, is one of 3 that started in 2019, is one of 6 in phase 3, and was the 2nd registered.

Hidradenitis Suppurativa

285 studies on the registry are indexed under Hidradenitis Suppurativa; 88 are open to participants now.

Browse Hidradenitis Suppurativa studies →

Open to participants now

9 of the 21 studies in Hidradenitis Suppurativa by Novartis are open now, in 12 countries. Recruiting first, the newest first:

4 more — sign in →

By country, each count listing its studies:

All 9 open studies →

Who these studies take

Of the 61 Hidradenitis Suppurativa studies recruiting now, 33 (54%) set no upper age limit and 17 (28%) stop at 75 or younger; 13 take children under 18; 12 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 21 studies in Hidradenitis Suppurativa by Novartis, or all of them as a file.
02

Study summary

The purpose of this study was to demonstrate superiority of secukinumab at Week 16, based on Hidradenitis Suppurativa Clinical Response (HiSCR) rates versus placebo, along with the maintenance of efficacy of secukinumab at Week 52 in subjects with moderate to severe HS. Moreover, this study also assessed the safety and tolerability of secukinumab.

Read the detailed description

This was a multicenter, randomized, double-blind, placebo-controlled, parallel group study with two secukinumab dose regimens in 541 patients with moderate to severe HS. The study consisted of: screening (up to 4 weeks) treatment period 1 (16 weeks, active drug or placebo) and treatment period 2 (up to 1 year all patients on active drug); there was an optional extension study (NCT04179175). Adult males and females with moderate to severe HS were included, with a diagnosis of HS greater than 1 year prior to baseline. Dosing was once every 2 weeks, or once every 4 weeks via pre-filled syringe; periodic home-dosing is included.

In Treatment Period 1, participants were randomized to secukinumab Q2W, secukinumab Q4W, placebo Q2W or placebo Q4W in 1:1:0.5:0.5 ratio. In Treatment Period 2, at the Week 16 visit participants initially randomized to placebo were switched to one of the two active dose regimens (secukinumab Q2W or Q4W), while subjects randomized to secukinumab during Treatment Period 1 continued on the same dose.

At the Week 16 visit, subjects initially randomized to placebo were switched to one of the two active dose regimens (secukinumab Q2W or Q4W), while subjects randomized to secukinumab during Treatment Period 1 continued on the same dose.

The primary objective was to demonstrate the efficacy of secukinumab compared to placebo with respect to HISCR after 16 weeks of treatment; secondary objectives were to assess difference in proportion of patients with HS flares, and proportion of patients with clinical response in HS related skin pain after 16 weeks of treatment. Key safety data was collected, along with Patient Reported Outcomes.

03

Conditions studied

  • Hidradenitis Suppurativa

Keywords

  • acne inversa
  • Hidradenitis suppurativa
  • maladie de Verneuil
  • inflammatory disease
  • AIN457
  • AIN457M
  • secukinumab
  • HS
  • lumps
  • skin
  • lesions
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Written must be obtained before any assessment is performed.
  • Male and female patients ≥ 18 years of age.
  • Diagnosis of HS ≥ 1 year prior to baseline.
  • Patients with moderate to severe HS defined as:
  • A total of at least 5 inflammatory lesions, i.e. abscesses and/or inflammatory nodules AND
  • Inflammatory lesions should affect at least 2 distinct anatomic areas
  • Patients agree to daily use of topical over-the-counter antiseptics on the areas affected by HS lesions while on study treatment.

Exclusion criteria

Exclusion Criteria:

  • Total fistulae count ≥ 20 at baseline.
  • Any other active skin disease or condition that may interfere with assessment of HS.
  • Active ongoing inflammatory diseases other than HS that require treatment with prohibited medications.
  • Use or planned use of prohibited treatment. detailed in the protocol have to be adhered to.
  • History of to any of the study drug constituents.
  • History of lymphoproliferative disease or any known or history of malignancy of any organ system treated or untreated within the past 5 years, regardless of whether there is evidence of local recurrence or (except for skin Bowen's disease, or basal cell carcinoma or actinic keratoses that have been treated with no evidence of recurrence in the past 12 weeks; carcinoma in situ of the cervix or non-invasive malignant colon polyps that have been removed).
  • Pregnant or lactating women.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
544 participants (actual)

Study arms

  • Active comparator
    secukinumab 1

    Secukinumab 300mg every 2 weeks

    Drug: secukinumab

  • Active comparator
    secukinumab 2

    Secukinumab 300mg every 4 weeks

    Drug: secukinumab

  • Placebo comparator
    placebo 1

    Placebo group to secukinumab 300mg every 2 weeks

    Drug: Placebo

  • Placebo comparator
    placebo 2

    Placebo group to secukinumab 300mg every 4 weeks

    Drug: Placebo

Interventions

  • Secukinumab 300mg every 2 or every 4 weeks

    Also known as: AIN457

  • DrugPlacebo

    Placebo 300mg every 2 or every 4 weeks

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With Hidradenitis Suppurativa Clinical Response (HiSCR50)

    HiSCR50 at Week 16 is defined as at least a 50% decrease in Abscess and inflammatory Nodule (AN) count compared to baseline with no increase in the number of abscesses and/or in the number of draining fistulas from baseline to Week 16. The baseline is defined as the last assessment (including unscheduled visits) obtained before/on the day of the first administration of the study treatment, or on the randomization date if there had been no drug administration. This endpoint was analyzed by logistic regression.

    Time frame: 16 weeks

Secondary outcomes

  1. Percentage Change From Baseline in AN50 Count at Week 16

    The HS affected areas, e.g. right and left axillary (armpit), right and left gluteal ("buttock"), right and left inguinal-femoral (groin), perineal, pubic, sternal, right and left sub-mammary (breast) and others were assessed by the physician for abscesses, inflammatory nodules, draining fistulas, total fistulas, and other lesions. Inflammatory lesions, including abscesses, nodules, draining fistulae, total fistulae and other lesions were counted. The analysis method for percentage change from baseline in abscesses and inflammatory nodules (AN) count at Week 16 was an ANCOVA model.

    Time frame: Baseline, 16 weeks

  2. Percentage of Participants With Hidradenitis Suppurativa (HS) Flares

    Percentage of participants who experience at least one flare over 16 weeks. A flare is defined as at least a 25% increase in abscesses and inflammatory nodules (AN) count with a minimum increase of 2 AN relative to baseline. This endpoint was analyzed by logistic regression.

    Time frame: 16 weeks

  3. Percentage of Participants Achieving NRS30

    Patients achieving Numerical Rating Scale score of 30 (NRS30) at week 16, defined as at least a 30% reduction and at least one unit reduction from baseline in the Patient's Global assessment of Skin Pain (where range 0 \[no skin pain\] to 10 \[worst skin pain\]). This endpoint was analyzed by logistic regression.

    Time frame: Baseline, week 16

07

Results

Posted Sep 25, 2024

Participant flow

Treatment Period 1 (Until Week 16)
Participant flow — Treatment Period 1 (Until Week 16)
MilestoneSecukinumab - Q2WSecukinumab - Q4WPlaceboPlacebo - Re-randomized to Secukinumab Q2WPlacebo - Re-randomized to Secukinumab Q4W
Started18218118100
Full analysis set (fas)18118018000
Completed16816917200
Not completed1412900
Withdrew: Adverse event40100
Withdrew: Lost to follow-up31100
Withdrew: Physician decision11100
Withdrew: Technical problems10000
Withdrew: Withdrawal by subject49500
Withdrew: Misrandomized00100
Withdrew: Severe gcp violation11000
Treatment Period 2 (After Week 16)
Participant flow — Treatment Period 2 (After Week 16)
MilestoneSecukinumab - Q2WSecukinumab - Q4WPlaceboPlacebo - Re-randomized to Secukinumab Q2WPlacebo - Re-randomized to Secukinumab Q4W
Started16816908587
Completed13113706875
Not completed373201712
Withdrew: Adverse event65012
Withdrew: Pregnancy10010
Withdrew: Withdrawal by subject26200106
Withdrew: Poor efficacy12021
Withdrew: Lost to follow-up33022
Withdrew: Physician decision02011

Outcome measures

PrimaryPercentage of Participants With Hidradenitis Suppurativa Clinical Response (HiSCR50)

HiSCR50 at Week 16 is defined as at least a 50% decrease in Abscess and inflammatory Nodule (AN) count compared to baseline with no increase in the number of abscesses and/or in the number of draining fistulas from baseline to Week 16. The baseline is defined as the last assessment (including unscheduled visits) obtained before/on the day of the first administration of the study treatment, or on the randomization date if there had been no drug administration. This endpoint was analyzed by logistic regression.

Time frame:
16 weeks
Reported as:
Number · Percentage of participants
Percentage of Participants With Hidradenitis Suppurativa Clinical Response (HiSCR50)
Percentage of participantsSecukinumab 1 - Q2WSecukinumab 2 - Q4WPlacebo
Percentage of Participants With Hidradenitis Suppurativa Clinical Response (HiSCR50)45.041.833.7
Statistical analysis
  • Secukinumab 1 - Q2W vs Placebo · Regression, Logistic · p = 0.0070 · Odds ratio, log: 1.75 · 95% CI 1.12 to 2.73
  • Secukinumab 2 - Q4W vs Placebo · Regression, Logistic · p = 0.0418 · Odds ratio (or): 1.48 · 95% CI 0.95 to 2.32
SecondaryPercentage Change From Baseline in AN50 Count at Week 16

The HS affected areas, e.g. right and left axillary (armpit), right and left gluteal ("buttock"), right and left inguinal-femoral (groin), perineal, pubic, sternal, right and left sub-mammary (breast) and others were assessed by the physician for abscesses, inflammatory nodules, draining fistulas, total fistulas, and other lesions. Inflammatory lesions, including abscesses, nodules, draining fistulae, total fistulae and other lesions were counted. The analysis method for percentage change from baseline in abscesses and inflammatory nodules (AN) count at Week 16 was an ANCOVA model.

Time frame:
Baseline, 16 weeks
Reported as:
Least squares mean · percentage change from baseline
Percentage Change From Baseline in AN50 Count at Week 16
percentage change from baselineSecukinumab 1 - Q2WSecukinumab 2 - Q4WPlacebo
Percentage Change From Baseline in AN50 Count at Week 16-46.8 ± 3.33-42.4 ± 4.01-24.3 ± 4.33
Statistical analysis
  • Secukinumab 1 - Q2W vs Placebo · ANCOVA · p = <0.0001 · Least square mean difference: -23.05 · 95% CI -33.90 to -12.21
  • Secukinumab 2 - Q4W vs Placebo · ANCOVA · p = 0.0004 · Least square mean difference: -18.46 · 95% CI -29.32 to -7.60
SecondaryPercentage of Participants With Hidradenitis Suppurativa (HS) Flares

Percentage of participants who experience at least one flare over 16 weeks. A flare is defined as at least a 25% increase in abscesses and inflammatory nodules (AN) count with a minimum increase of 2 AN relative to baseline. This endpoint was analyzed by logistic regression.

Time frame:
16 weeks
Reported as:
Number · Percentage of participants
Percentage of Participants With Hidradenitis Suppurativa (HS) Flares
Percentage of participantsSecukinumab 1 - Q2WSecukinumab 2 - Q4WPlacebo 2
Percentage of Participants With Hidradenitis Suppurativa (HS) Flares15.423.229.0
Statistical analysis
  • Secukinumab 1 - Q2W vs Placebo 2 · Regression, Logistic · p = 0.0010 · Odds ratio, log: 0.42 · 95% CI 0.25 to 0.73
  • Secukinumab 2 - Q4W vs Placebo 2 · Regression, Logistic · p = 0.0926 · Odds ratio (or): 0.71 · 95% CI 0.43 to 1.17
SecondaryPercentage of Participants Achieving NRS30

Patients achieving Numerical Rating Scale score of 30 (NRS30) at week 16, defined as at least a 30% reduction and at least one unit reduction from baseline in the Patient's Global assessment of Skin Pain (where range 0 \[no skin pain\] to 10 \[worst skin pain\]). This endpoint was analyzed by logistic regression.

Time frame:
Baseline, week 16
Reported as:
Number · Percentage of participants
Percentage of Participants Achieving NRS30
Percentage of participantsSecukinumab 1 - Q2WSecukinumab 2 - Q4WPlacebo
Percentage of Participants Achieving NRS3034.132.223.8
Statistical analysis
  • Secukinumab 1 - Q2W vs Placebo · Regression, Logistic · p = 0.0248 · Odds ratio (or): 1.84 · 95% CI 1.00 to 3.40
  • Secukinumab 2 - Q4W vs Placebo · Regression, Logistic · p = 0.0044 · Odds ratio, log: 1.77 · 95% CI 1.15 to 2.0

Adverse events

Collected over Adverse events (AEs) were reported from first dose of study treatment, up to approximately 60 weeks for AIN457 (up to 52 weeks for subjects moving to extension study) and 16 weeks for placebo.. Non-serious events are listed at a 2% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
AIN457 Q2W0/181 (0%)13/181 (7.2%)135/181 (74.6%)
AIN457 Q4W0/180 (0%)9/180 (5%)132/180 (73.3%)
Placebo0/180 (0%)6/180 (3.3%)88/180 (48.9%)
Any AIN457 Q2W0/266 (0%)18/266 (6.8%)184/266 (69.2%)
Any AIN457 Q4W0/267 (0%)19/267 (7.1%)183/267 (68.5%)
Any AIN4570/533 (0%)37/533 (6.9%)367/533 (68.9%)
Most frequent serious events
Showing 10 of 41
Most frequent serious events
EventAIN457 Q2WAIN457 Q4WPlaceboAny AIN457 Q2WAny AIN457 Q4WAny AIN457
Sweat gland infectionInfections and infestations1/1813/1800/1801/2663/2674/533
HidradenitisSkin and subcutaneous tissue disorders3/1813/1802/1804/2664/2678/533
PneumoniaInfections and infestations0/1810/1800/1800/2662/2672/533
PericarditisCardiac disorders0/1811/1800/1800/2661/2671/533
AppendicitisInfections and infestations0/1811/1800/1801/2661/2672/533
Breast cellulitisInfections and infestations0/1811/1800/1800/2661/2671/533
CellulitisInfections and infestations1/1811/1800/1801/2661/2672/533
Post procedural infectionInfections and infestations0/1811/1800/1800/2661/2671/533
Urinary tract infectionInfections and infestations0/1811/1800/1800/2661/2671/533
C3 glomerulopathyRenal and urinary disorders0/1811/1800/1800/2661/2671/533
Most frequent other events
Showing 10 of 60
Most frequent other events
EventAIN457 Q2WAIN457 Q4WPlaceboAny AIN457 Q2WAny AIN457 Q4WAny AIN457
HeadacheNervous system disorders33/18132/18014/18039/26646/26785/533
NasopharyngitisInfections and infestations32/18124/18013/18040/26629/26769/533
HidradenitisSkin and subcutaneous tissue disorders16/18117/18023/18028/26626/26754/533
DiarrhoeaGastrointestinal disorders11/18116/1809/18012/26624/26736/533
Upper respiratory tract infectionInfections and infestations9/18113/1804/18012/26617/26729/533
PyrexiaGeneral disorders13/1818/1802/18016/26612/26728/533
FatigueGeneral disorders6/18111/1808/1808/26613/26721/533
ArthralgiaMusculoskeletal and connective tissue disorders11/1816/1808/18014/2669/26723/533
PruritusSkin and subcutaneous tissue disorders11/1816/1802/18015/2668/26723/533
IntertrigoSkin and subcutaneous tissue disorders10/1817/1802/18011/2668/26719/533

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)Secukinumab 1 - Q2WSecukinumab 2 - Q4WPlaceboTotal
<=18 years0000
Between 18 and 65 years178177179534
>=65 years3317
Age, Continuous
Age, Continuous(years)Secukinumab 1 - Q2WSecukinumab 2 - Q4WPlaceboTotal
Mean37.1 ± 12.5335.7 ± 11.7135.5 ± 10.7536.1 ± 11.69
Sex: Female, Male
Sex: Female, Male(Participants)Secukinumab 1 - Q2WSecukinumab 2 - Q4WPlaceboTotal
Female102100102304
Male798078237
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Secukinumab 1 - Q2WSecukinumab 2 - Q4WPlaceboTotal
White145146139430
Black or African American15101237
Asian19232466
American Indian or Alaska Native1124
Multiple1034
08

Study locations

111 sites
  • Novartis Investigative Site
    Birmingham, Alabama 35205, United States
  • Novartis Investigative Site
    Rogers, Arkansas 72758, United States
  • Novartis Investigative Site
    Anaheim, California 92807, United States
  • Novartis Investigative Site
    San Diego, California 92123, United States
  • Novartis Investigative Site
    Miami, Florida 33125, United States
  • Novartis Investigative Site
    Tampa, Florida 33612, United States
  • Novartis Investigative Site
    Glenview, Illinois 60077, United States
  • Novartis Investigative Site
    West Dundee, Illinois 60118, United States
  • Novartis Investigative Site
    Boston, Massachusetts 02215, United States
  • Novartis Investigative Site
    New Brighton, Minnesota 55112, United States
  • Novartis Investigative Site
    Saint Joseph, Missouri 64506, United States
  • Novartis Investigative Site
    Chapel Hill, North Carolina 27516, United States
  • Novartis Investigative Site
    Fairborn, Ohio 45324, United States
  • Novartis Investigative Site
    Pittsburgh, Pennsylvania 15213-3403, United States
  • Novartis Investigative Site
    Charleston, South Carolina 29407, United States
  • Novartis Investigative Site
    Goodlettsville, Tennessee 37072-2301, United States
  • Novartis Investigative Site
    Dallas, Texas 75246-1613, United States
  • Novartis Investigative Site
    San Antonio, Texas 78229, United States
  • Novartis Investigative Site
    Ciudad Autonoma de Bs As, Buenos Aires C1425BEA, Argentina
  • Novartis Investigative Site
    La Plata, Buenos Aires B1902COS, Argentina
  • Novartis Investigative Site
    Buenos Aires, C1425DKG, Argentina
  • Novartis Investigative Site
    Phillip, Australian Capital Territory 2606, Australia
  • Novartis Investigative Site
    Benowa, Queensland 4217, Australia
  • Novartis Investigative Site
    East Melbourne, Victoria 3002, Australia
  • Novartis Investigative Site
    Linz, 4020, Austria
  • Novartis Investigative Site
    Wien, A 1090, Austria
  • Novartis Investigative Site
    Bruxelles, Brussels 1070, Belgium
  • Novartis Investigative Site
    Sofia, 1606, Bulgaria
  • Novartis Investigative Site
    Stara Zagora, 6000, Bulgaria
  • Novartis Investigative Site
    London, Ontario N6H 5L5, Canada
  • Novartis Investigative Site
    Peterborough, Ontario K9J 5K2, Canada
  • Novartis Investigative Site
    Waterloo, Ontario N2J 1C4, Canada
  • Novartis Investigative Site
    Prague, Prague 1 11000, Czechia
  • Novartis Investigative Site
    Plzen, 30460, Czechia
  • Novartis Investigative Site
    Bordeaux Cedex, 33075, France
  • Novartis Investigative Site
    Brest, 29609, France
  • Novartis Investigative Site
    Creteil, 94010, France
  • Novartis Investigative Site
    Lyon, 69437, France
  • Novartis Investigative Site
    Montpellier, 34295, France
  • Novartis Investigative Site
    Nantes Cedex 1, 44093, France
  • Novartis Investigative Site
    Paris 10, 75475, France
  • Novartis Investigative Site
    Toulouse, 31400, France
  • Novartis Investigative Site
    Bielefeld, 33647, Germany
  • Novartis Investigative Site
    Bochum, 44791, Germany
  • Novartis Investigative Site
    Frankfurt, 60590, Germany
  • Novartis Investigative Site
    Halle Saale, 06108, Germany
  • Novartis Investigative Site
    Langenau, 89129, Germany
  • Novartis Investigative Site
    Memmingen, 87700, Germany
  • Novartis Investigative Site
    Muenchen, 80377, Germany
  • Novartis Investigative Site
    Potsdam, 14467, Germany
  • Novartis Investigative Site
    Athens, 12462, Greece
  • Novartis Investigative Site
    Thessaloniki, 546 43, Greece
  • Novartis Investigative Site
    Budapest, 1085, Hungary
  • Novartis Investigative Site
    Pecs, 7623, Hungary
  • Novartis Investigative Site
    New Delhi, Delhi 110 060, India
  • Novartis Investigative Site
    Mangalore, Karnataka 575002, India
  • Novartis Investigative Site
    Mysore, Karnataka 570001, India
  • Novartis Investigative Site
    Nashik, Maharashtra 422 101, India
  • Novartis Investigative Site
    Jerusalem, 9112001, Israel
  • Novartis Investigative Site
    Petach Tikva, 4941492, Israel
  • Novartis Investigative Site
    Firenze, FI 50122, Italy
  • Novartis Investigative Site
    Milano, MI 20122, Italy
  • Novartis Investigative Site
    Modena, MO 41124, Italy
  • Novartis Investigative Site
    Pisa, PI 56124, Italy
  • Novartis Investigative Site
    Nagoya-city, Aichi 467-8602, Japan
  • Novartis Investigative Site
    Kisarazu, Chiba 292-8535, Japan
  • Novartis Investigative Site
    Nakagami, Okinawa 903 0215, Japan
  • Novartis Investigative Site
    Koshigaya, Saitama 343-8555, Japan
  • Novartis Investigative Site
    Itabashi-ku, Tokyo 173-8610, Japan
  • Novartis Investigative Site
    Osaka, 545-8586, Japan
  • Novartis Investigative Site
    Seoul, 02841, Korea, Republic of
  • Novartis Investigative Site
    Seoul, 03080, Korea, Republic of
  • Novartis Investigative Site
    Seoul, 07441, Korea, Republic of
  • Novartis Investigative Site
    Guadalajara, Jalisco 44657, Mexico
  • Novartis Investigative Site
    Monterrey, Nuevo Leon 64460, Mexico
  • Novartis Investigative Site
    Davao City, Davao 8000, Philippines
  • Novartis Investigative Site
    Quezon City, Metro Manila 1104, Philippines
  • Novartis Investigative Site
    Las Pinas, 1740, Philippines
  • Novartis Investigative Site
    Warszawa, Mazowian 02 495, Poland
  • Novartis Investigative Site
    Ossy, 42 624, Poland
  • Novartis Investigative Site
    Wroclaw, 50 566, Poland
  • Novartis Investigative Site
    Lisboa, 1169 050, Portugal
  • Novartis Investigative Site
    Lisboa, 1998-018, Portugal
  • Novartis Investigative Site
    Matosinhos, 4454 513, Portugal
  • Novartis Investigative Site
    Porto, 4099-001, Portugal
  • Novartis Investigative Site
    Kazan, 420012, Russian Federation
  • Novartis Investigative Site
    Krasnodar, 350020, Russian Federation
  • Novartis Investigative Site
    Saint Petersburg, 197022, Russian Federation
  • Novartis Investigative Site
    Yaroslavl, 150003, Russian Federation
  • Novartis Investigative Site
    Kosice, Slovak Republic 4190, Slovakia
  • Novartis Investigative Site
    Martin, 03659, Slovakia
  • Novartis Investigative Site
    Cadiz, Andalucia 11009, Spain
  • Novartis Investigative Site
    Alicante, Comunidad Valenciana 03010, Spain
  • Novartis Investigative Site
    Fuenlabrada, Madrid 28942, Spain
  • Novartis Investigative Site
    Barcelona, 08041, Spain
  • Novartis Investigative Site
    Madrid, 28041, Spain
  • Novartis Investigative Site
    Pontevedra, 36003, Spain
  • Novartis Investigative Site
    Uppsala, 751 85, Sweden
  • Novartis Investigative Site
    Bern, 3010, Switzerland
  • Novartis Investigative Site
    Geneve, 1205, Switzerland

Showing the first 100 of 111 sites across 29 countries. Choose a country and city above to see the rest.

09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations. This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jan 2019 to primary completion in Oct 2021, 32 months.

Results were first posted in Sep 2024, 2 years 11 months after primary completion. A results delay was requested in Jul 2021.

Of 26 phase 3 interventional studies under Hidradenitis Suppurativa, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 38. This study's 32 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 18, 2018
First posted
Oct 22, 2018
StartActual
Jan 31, 2019
Primary completionActual
Oct 1, 2021
CompletionActual
Jul 26, 2022
Results delay requested
Jul 8, 2021
Results first posted
Sep 25, 2024
Last update
Oct 9, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 9, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03713619
Responsible party
Sponsor
First posted
Oct 22, 2018
Start date
Jan 31, 2019
Primary completion
Oct 1, 2021
Completion
Jul 26, 2022
Results posted
Sep 25, 2024
Last update
Oct 9, 2024

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Secukinumab

Start the discussion